ен с плацебо [съответно 3 пациенти (1, 4%) спрямо 77 пациенти (35%)].
Fondaparinux provided a significant reduction in the overall rate of VTE compared with placebo [3 patients (1.4%) vs 77 patients (35%), respectively].